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Objectives: The current method for testing new drugs against tuberculosis in vivo is the enumeration of
bacteria in organs by cfu assay. Owing to the slow growth rate of Mycobacterium tuberculosis (Mtb), these
assays can take months to complete. Our aim was to develop a more efficient, fluorescence-based imaging
assay to test new antibiotics in a mouse model using Mtb reporter strains.
Methods: A commercial IVIS Kineticw system and a custom-built laser scanning system with fluorescence
molecular tomography (FMT) capability were used to detect fluorescent Mtb in living mice and lungs ex vivo.
The resulting images were analysed and the fluorescence was correlated with data from cfu assays.
Results:We have shown that fluorescent Mtb can be visualized in the lungs of living mice at a detection limit of
8×107 cfu/lung, whilst in lungs ex vivo a detection limit of 2×105 cfu/lung was found. These numbers were
comparable between the two imaging systems. Ex vivo lung fluorescence correlated to numbers of bacteria in
tissue, and the effect of treatment of mice with the antibiotic moxifloxacin could be visualized and quantified
after only 9 days through fluorescence measurements, and was confirmed by cfu assays.
Conclusions:We have developed a new and efficient method for anti-tuberculosis drug testing in vivo, based on
fluorescent Mtb reporter strains. Using this method instead of, or together with, cfu assays will reduce the time
required to assess the preclinical efficacy of new drugs in animal models and enhance the progress of these
candidates into clinical trials against human tuberculosis.
Keywords: antibiotics, drug testing, mycobacteria, optical imaging, TB
Introduction
Tuberculosis (TB) is still among the most prevalent infectious dis-
eases worldwide, causing 1.7 million deaths globally in 2009,
and is currently estimated to infect one-third of the world’s
population.1 Control strategies to prevent further spread of the
disease include prompt detection, treatment and prophylactic
vaccination. The only vaccine currently available against TB is
Mycobacterium bovis bacille Calmette–Gue´rin (BCG), which has
been used safely for decades but is not effective against pulmon-
ary TB in tropical countries, and is contraindicated in people
infected with HIV.2,3 Antibiotic treatment is available, but regi-
mens require administration of two or three drugs for 6–
9 months, and full completion is necessary to minimize the risk
of evolving drug-resistant strains. This requires high patient com-
pliance, and a steady supply of drugs, and the latter cannot
always be guaranteed in low-income countries. Mycobacterium
tuberculosis (Mtb) strains resistant to a single drug have
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emerged in every country surveyed, and multidrug-resistant
strains, defined as strains resistant to at least isoniazid and ri-
fampicin, are prevalent, particularly in Eastern Europe.1 In add-
ition, 57 countries worldwide had reported at least one case of
TB caused by an extensively drug-resistant (XDR) strain, resistant
to first- and second-line drugs, by September 2009.4 The
increase in drug resistance and the lack of an effective vaccine
against adult TB are serious threats to the control of TB, creating
a great need to identify and develop new anti-TB drugs and
vaccines.
Preclinical in vivo models are needed to test new drugs for
both their efficacy and their pharmacodynamics and pharmaco-
kinetics, which cannot be achieved in vitro. This is particularly
important in TB as immunopathology leads to the formation of
granulomatous lesions in patients during the course of the
disease.5,6 These rigid structures are thought to sequestrate
the bacilli and prevent spread throughout the body; however,
they could also prevent drugs from penetrating into the tissue
and reaching the target bacteria. Mouse models of TB are well
established and provide suitable and convenient tools for early
stage drug screening, although the lesions formed in the
mouse lung can differ from those in TB patients.7,8 However,
pathology still occurs and can lead to gross changes in the
tissue morphology of the infected mouse lung.9,10 Another fact
that needs to be considered when testing new drugs is that
mycobacteria can alter their metabolic state during growth
and persistence inside the host tissue and can switch to a less
active or dormant state in which they may become less suscep-
tible to antibiotics.11 Different mouse models of TB exist which
resemble certain aspects of human TB, including those for
granuloma necrosis and hypoxia in C3HeB/FeJ mice, a variety
of models for chronic or latent infection, as well as for active pro-
gressive infection in the absence of adaptive immunity in severe
combined immunodeficiency (SCID) mice.9,12
To assess the efficacy of a new anti-TB drug in mice, bacterial
viability and growth has been measured to date by cfu assays in
target organs such as the lung and spleen. This method is reli-
able and accurate, but it is time-consuming and labour-intensive
and provides only retrospective data, as mycobacterial colonies
can take up to 6 weeks to become countable. Moreover, cfu
assays are endpoint measurements, which require killing the
animal. This not only increases the number of animals required
and the cost, thereby decreasing the number of drug candidates
that can be screened at any one time within the limited aerosol
containment space available at most animal facilities, but also
prohibits a further follow-up of an individual animal for long-
lasting drug effects or remission. In contrast, biophotonic
imaging (BPI) of bioluminescent or fluorescently labelled bac-
teria would enable an instant assessment of bacterial load and
location by using highly sensitive cameras to directly measure
the visible light produced by these microorganisms. By utilizing
labelled strains that maintain the virulent traits of the parental
Mtb strain in a mouse infection model, this should help to
speed up the process of drug screening. It would allow longitu-
dinal studies in which individual animals can be followed over
time, and therefore helping to reduce the number of animals
needed and to decrease the variation in the data.13–17 BPI
has been used extensively to monitor the progression of other
bacterial infections, bacterial gene expression and the effect of
vaccines or drugs.18 Although bioluminescence was used in the
majority of these studies, both methods have their advantages
and disadvantages. Bioluminescence provides a superior
signal-to-noise ratio and, due to its enzymatic nature, allows
the rapid detection of changes in microbial metabolism.19 In
contrast, fluorescent proteins (FPs) do not rely on co-factors or
administration of an exogenous substrate (which may be
subject to tissue penetration issues), bacterial colonies are
often characterized by a coloured appearance,20 which is a con-
venient indicator of marker protein expression, and results
obtained by in vivo imaging can easily be followed up by fluores-
cence microscopy once animals are killed. Absorption and conse-
quently penetration of light through tissue is a challenging issue
for in vivo imaging approaches. Absorption of light is dependent
on wavelength and tissue type. Light of longer wavelengths
travels better through tissue, and blood-rich tissue absorbs light
more efficiently than less vascularized tissue. Importantly,
absorption drops rapidly between the wavelengths of 580 and
650 nm.21 Therefore, the use of red FPs is favoured for in vivo
imaging over green or yellow FPs, but often green FP (GFP) is the
reporter of choice, whereas the use of red FPs (RFPs) for infectious
disease models is still rare.18 The red fluorescent reporter strains
of Mtb in combination with the instrumentation described in this
study are expected to allow visualization of fluorescent signals
up to 0.5 cm deep in lung tissue.
The purpose of this study was to develop a fluorescence-based
imaging assay using reporter strains of Mtb to expedite and facili-
tate in vivo testing of anti-TB drugs. We have previously described
the development ofMtb strains expressing RFPs.20 Herewe charac-
terized these fluorescent strains for in vivo and ex vivo imaging in
an immune-compromisedmousemodel of infection, which allows
the progressive growth ofMtb, using a commercially available IVIS
Kineticw system to provide proof of principle that fluorescence
imaging can be employed to evaluate the efficacy of new
anti-TB drugs in vivo. To verify IVIS results and improve the reso-
lution of images, we used a custom-built laser scanning (LS)
system. Our aim was to assess the feasibility and sensitivity of
fluorescence imaging for monitoring the course of Mtb infection
inmice and the impact of antibiotic treatment on bacterial burden.
Materials and methods
Bacterial strains and culture conditions
Bacterial strains, plasmids and FPs used in this study are summarized in
Table 1. Construction of reporter plasmids was described previously in
detail.20 Briefly, the promoter Psmyc was amplified by PCR from pSE100
and cloned into the vector pSMT3 to generate pSMT3-S via BamHI/XbaI
restriction sites.22,23 In the case of pCherry10, the G13 promoter from
Mycobacterium marinum was used to generate pSMT3-G13. mCherry,
tdTomato and Turbo-635 sequences were codon-optimized for Mtb
codon preferences, synthesized (Genscript USA Inc., Piscataway, USA)
and cloned into pSMT3-S via BamHI/HindIII restriction sites to generate
pCherry3, pAsta3 and pCharge3, respectively. mCherry was cloned into
pSMT3-G13 via BamHI/HindIII restriction sites to generate pCherry10.
Subsequently plasmids were electroporated into the Mtb H37Rv parental
strain (ATCC 25618) as described previously.20,22,24
Mtb wild-type (WT) strain H37Rv and its fluorescent derivatives
Charge3, Cherry3, Cherry10 and Asta3 were cultured in Middlebrook
7H9 medium (Sigma-Aldrich, Taufkirchen, Germany) containing 10%
Middlebrook OADC (oleic acid, albumin, dextrose, catalase) supplement
(BD, Heidelberg, Germany) and 0.5% glycerol (Sigma-Aldrich) without
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agitation or on Middlebrook 7H11 agar plates (BD) containing 10%
Middlebrook OADC supplement and 0.5% glycerol. Hygromycin B
(100 mg/L; Sigma-Aldrich, Gillingham, UK) was added to the culture
media or plates when required, as described previously.20 Bacterial
cultures were washed oncewith 1×PBS, resuspended in 1×PBS+10% gly-
cerol, aliquoted, frozen and stored at 2808C for later use. The number of
viable bacteria in frozen stocks was determined by plating a series of
10-fold dilutions on 7H11 agar plates and enumeration of colonies after
4–6 weeks of incubation at 378C. To prepare the inocula for infection of
mice, bacteria were thawed, washed once with 1×PBS and resuspended
in 1×PBS to the required concentration.
Infection of animals
All experiments were performed in accordance with the German Animal
Protection Law and under ABSL3 aerosol containment. Animal experi-
ments were approved by the Ethics Committee for Animal Experiments
of the Ministry for Agriculture, Environment, and Rural Areas of the State
of Schleswig-Holstein (Kommission fu¨r Tierversuche/Ethik-Kommission
des Landes Schleswig-Holstein) under the licenses 13–2/10 (‘Analyse
von Reportersta¨mmen des Tuberkuloseerregers’/‘Analysis of reporter
strains of the causative agent of tuberculosis’) and 39–4/11 (‘Testung
von Moxifloxacin gegen Tuberkulose mittels in vivo Imaging’/‘Testing of
moxifloxacin against tuberculosis by in vivo imaging’).
Six- to 12-week-old CB-17 SCID mice or SCID Hairless Outbred (SHO)
mice (Charles River, Germany) were anaesthetized with a ketamine
(125 mg/kg, WDT, Garbsen, Germany) and Rompun (2.5 mg/kg, active in-
gredient xylazine; Bayer, Leverkusen, Germany) solution by intraperito-
neal injection, and infected with parental Mtb H37Rv or its fluorescent
derivatives in 20 mL of PBS via the intranasal route, with inocula as indi-
cated in the figure legends. The input inocula were confirmed by plating
10-fold dilutions onto 7H11 agar plates containing 10% OADC supple-
ment and 0.5% glycerol, and incubating for 6 weeks at 378C.
Moxifloxacin treatment
To prepare the moxifloxacin solution, 20% Captisol (w/v; Cydex Pharma,
Lenaxa, USA) was dissolved in water. Moxifloxacin (Apin Chemicals
Limited, Abingdon, UK) was then added to a final concentration of
5000 mg/L and the solution was sterile filtered. Mice were given seven
daily doses of 50 mg/kg body weight of moxifloxacin by oral gavage,
starting 1 day after infection.
Imaging of animals and organs
All imaging was performed in an ABSL3 aerosol containment laboratory
in accordance with local safety regulations.
To increase the signal-to-noise ratio in animals used for imaging, fur
was removed from the thoracic area approximately once a week. The
mice were anaesthetized with a ketamine and xylazine solution by intra-
peritoneal injection as described above. Once fully unconscious, a depil-
ating cream (Veet, Slough, UK) was applied and left for 5 min. The
cream was then removed with soft tissue paper to minimize skin
irritation and the area cleaned with water and soft tissue paper to
avoid non-specific fluorescence from residual cream.
On all other occasions when imaging was performed, mice were
anaesthetized with 4% isoflurane gas (Actavis, Munich, Germany) and,
once inside the camera chamber, anaesthesia was maintained by
administering 2%–3% isoflurane through individual nose cones.
Imaging of live animals or organs was performed using either an IVIS
Kineticw imaging system (Caliper Life Sciences, Preston Brook Runcorn,
UK) or a custom-built LS system. The IVIS system consisted of a cooled
charge-coupled device (CCD) camera mounted onto a light-tight speci-
men chamber. The fluorescent excitation light was provided by a
halogen lamp in combination with appropriate excitation filters. Emission
filters were placed in front of the camera aperture to allow recording of
specific wavelengths of light, depending on the emission spectra of the FP
examined. Non-specific fluorescence was recorded by using a lower
wavelength excitation filter and subtracted from original images by
using the Image Math Tool in Living Image software (version 3.2,
Caliper Life Sciences). The corrected image was then superimposed
onto a greyscale reference photograph taken under low illumination
using the Living Image software to aid the determination of the anatom-
ical location of the signal. Fluorescence was quantified on the raw data
before non-specific fluorescence was removed, by using the Region of
Interest (ROI) tool in the Living Image software, where only light eman-
ating from within a specified area was measured. Images were acquired
using the following settings unless otherwise stated: excitation filter
605 nm and emission filter 660 nm (Charge3, Cherry3, Cherry10) or
excitation filter 570 nm and emission filter 620 nm (Asta3); background
excitation filter 465 nm; f-stop 1.2; binning 4; exposure time 3–10 s.
Fluorescence intensity was displayed on a pseudocolour spectrum
(where dark red represents the lowest intensity and yellow the highest)
and presented as efficiency, a measurement normalized to the incident
excitation intensity (efficiency¼radiance of the subject/illumination in-
tensity). By displaying fluorescence as efficiency, images taken at differ-
ent timepoints and with different exposure times could be directly
compared with each other.
The LS system comprised a similar configuration, with a CCD camera
(iKonM; Andor Technology, Belfast, Northern Ireland) placed on top of a
light-tight specimen chamber and emission filters in front of the
camera aperture. The fluorescent excitation light was provided by a
593 nm laser (RGBLase LLC, Fremont, California, USA), which was
guided onto the specimen by several mirrors. Fine movement of the
laser beam was controlled by a Scancubew7 scan head (Scanlab,
Table 1. Summary of bacterial strains used in this study, as described previously20
Strain FP expressed Plasmid
Quantum
yield of FP
Excitation coefficient
of FP (M21 cm21)
Brightness of FP
(% of DsRed)
l of FP (nm)a
ex em
H37Rv none NA NA NA NA NA NA
Cherry3 mCherry26 pCherry3 (Psmyc promoter; Addgene plasmid 24659) 0.22 72000 27 587 610
Cherry10 mCherry26 pCherry10, (G13 promoter; Addgene plasmid 24664) 0.22 72000 27 587 610
Charge3 Turbo-63527 pCharge3(Psmyc promoter; Addgene plasmid 24658) 0.34 65000 37 588 635
Asta3 tdTomato26 pAsta3 (Psmyc promoter; Addgene plasmid 24657) 0.69 138000 160 554 581
l, wavelength; NA, not applicable.
aWavelengths are represented by maxima of excitation (ex) and emission (em) spectra.
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Puchheim/Munich, Germany). To acquire fluorescence images, the laser
was scanned across the whole specimen in one motion and a single
image was acquired using a specific emission filter to capture the total
fluorescence emission (centre wavelength 620 nm/bandwidth 40 nm or
centre wavelength 650 nm/bandwidth 60 nm; Chroma Technology,
Bellow Falls, Vermont, USA). The emission filter was then removed and
another image was acquired in the same way to yield an excitation
image. The fluorescence intensity was normalized by the median excita-
tion intensity across the image using Matlab software [version 7.7.0.471
(R2008b); MathWorks, Cambridge, UK], and the normalized fluorescence
image was superimposed onto a greyscale reference photograph.
Images were acquired with an exposure time of 2–3 s. Fluorescence
was quantified using ROI analysis. Fluorescence intensity was displayed
on a pseudocolour spectrum (where blue represents the lowest intensity
and yellow the highest) and presented as normalized fluorescence so
that images acquired with different exposure settings could be compared
directly.
When organs were imaged, they were placed as flatly as possible to
allow full and consistent light penetration in order to minimize potential
variation in the measurements due to different tissue thickness.
Enumeration of bacteria in tissues
At the specified timepoints, animals were killed by cervical dislocation
whilst under anaesthesia. Lungs and spleens were removed aseptically
and homogenized by mechanical disruption in sterile WTA buffer consist-
ing of 1% (w/v) BSA (Serva, Heidelberg, Germany), 1% (v/v) Tween 80
(Sigma-Aldrich) in sterile water. A cfu assay was performed by plating
a series of 10-fold dilutions of tissue homogenates onto 7H11 agar
plates with 10% OADC supplement and 0.5% glycerol. Bacteria were
grown on non-selective media to determine the stability of FP expression
by evaluating colony colour. Plates were incubated at 378C and colonies
counted after 8–12 weeks.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 4.02. To
compare fluorescence efficiencies or cfu burden between mice infected
with Mtb H37Rv WT or Mtb Charge3, a Mann–Whitney test was used.
For cfu, groups of five mice were compared. Where more than two
groups were compared, a Kruskal–Wallis test with Dunn’s post test for
multiple comparisons was performed. For analyses of in vivo fluorescence
efficiency, all animals were included in each analysis. To test the correl-
ation of cfu burden and fluorescent signal, a Pearson correlation test
was performed. Linear regression analysis was used to determine the re-
lationship between cfu and fluorescence.
Results
Red fluorescent proteins are stably expressed in
M. tuberculosis and do not attenuate growth in vivo
Light of longer wavelengths is better suited for in vivo imaging
than light of shorter wavelengths, because it penetrates deeper
into the tissue and causes less autofluorescence.25 We therefore
chose to investigate Mtb strains expressing the RFPs mCherry
(designated Cherry3 and Cherry10), Turbo-635 (designated
Charge3) or tdTomato (designated Asta3) for their suitability
for in vivo imaging (see Table 1).26,27 We have previously shown
that these strains express the marker proteins stably and at
high levels in vitro.20 Since the expression of exogenous proteins
often places a metabolic burden on the bacterial cell, which can
cause attenuation of virulence, we first compared the virulence
of these strains against the parental WT strain H37Rv. CB-17
SCID mice were infected with H37Rv WT or fluorescent reporter
strains via the intranasal route and the number of bacteria in
lungs and spleens was determined by cfu assay of organ homo-
genates during the course of infection (Figure 1). After 5 days,
comparable numbers of WT, Charge3, Cherry10 and Asta3 bac-
teria (105–106 cfu) were detected in lungs of CB-17 SCID
mice, whilst Cherry3 had grown significantly less than the
other strains (difference compared with Cherry3: H37Rv,
38-fold, P,0.05; Charge3, 27-fold, P.0.05; Cherry10, 51-fold,
P,0.01; Figure 1a), but this difference was absent at day 20
after infection, when all fluorescent strains had reached higher
mean lung cfu values than the WT (Figure 1b). Bacteria of all
tested strains were found to spread to the spleen at a later time-
point of infection, and the bacterial burden of fluorescent strains
was similar or higher than the WT (Figure 1c). From these data
we conclude that the expression of these RFPs did not attenuate
in vivo virulence of Mtb.
Fluorescent M. tuberculosis can be detected in mouse
lungs in vivo
To establish whether growth of the reporter strains could be
visualized in vivo, the CB-17 SCID mice infected above
(Figure 1) were imaged at day 16 or 20 after infection using an
IVIS imaging system before being killed for cfu enumeration.
On day 20, specific fluorescent signals were detected in the thor-
acic area of four out of five mice infected with Mtb Charge3,
whilst weak signals were found in two out of five mice infected
with Mtb Cherry3, and no signal was observed in mice infected
with Mtb Cherry10 or Asta3 (Figure 2). Mice infected with Mtb
H37Rv WT were imaged under the same conditions and served
as a negative control. No specific fluorescent signals were
detected in the thoracic area of these animals. Non-specific
fluorescence was detected in the abdominal area of some
animals, which most likely originated from food in the stomach
and intestinal tract. As the bacterial burden in the lungs of
infected animals was comparable between the different reporter
strains (Figure 1) and Mtb Charge3 produced the strongest fluor-
escent signal (Figure 2), this strain was selected for further
studies.
To further analyse the kinetics of infection and the limit of
bacterial detection, CB-17 SCID mice were infected intranasally
with Mtb Charge3, images were acquired on the IVIS system at
1, 7, 12 and 15 days post-infection, and bacterial loads in
lungs and spleens were determined by cfu assay (Figure 3). Fluor-
escence was quantified by ROI analysis in the Living Image soft-
ware over the thoracic area on raw data before non-specific
background was subtracted. One group of mice was infected
with Mtb H37Rv WT and served as a negative control for fluores-
cence imaging. The bacterial burden in lungs and spleens
increased steadily over time, reaching 4×107–2.3×108 cfu/lung
of Mtb Charge3 on day 15 (Figure 3b). Bacteria could be cultured
from spleens of all animals from day 13 onwards, reaching a
peak of 6×103–5.5×104 cfu/spleen at day 15 (Figure 3c).
Accordingly, the fluorescent signal emanating from the thoracic
area also increased over time in mice infected with Mtb Charge3
such that on days 12 and 15 after infection Mtb Charge3-
infected mice displayed significantly higher fluorescence than
mice infected with Mtb H37Rv WT (P¼0.0043 and P¼0.0020,
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respectively; Figure 3a and d). It should be noted that Figure 3(a)
depicts one representative group of mice to allow comparison of
the same group of five animals over time, whilst Figure 3(d)
shows the average fluorescence measured in all animals still in
the experiment at the respective timepoints. Therefore, fluores-
cence levels differ between Figure 3(a) and Figure 3(d). Images
of the groups of mice used for determination of cfu are shown
in Figure S1 (available as Supplementary data at JAC Online).
The fold increase in fluorescence in Mtb Charge3-infected mice
over the mice infected with the non-fluorescent Mtb H37Rv WT
was comparable on days 12 and 15 after infection (Figure 3d;
1.30-fold and 1.34-fold, respectively), which is in accordance
with the cfu data (Figure 3b). There was no detectable signal in
the spleen area, which was most likely due to the lower
numbers of bacteria present in this organ. Based on the observa-
tion that a specific signal was first evident on day 12 after infec-
tion (Figure 3a and d), we estimate the detection limit of Mtb
Charge3 in vivo to be 8×107 cfu/lung.
Stability of FP expression was analysed for Mtb Charge3 at
each timepoint when cfu were determined, by visually scoring
whether bacterial colonies were coloured or not (Table 2). More
than 90% of bacteria expressed the FP throughout the course
of the infection, in both lung and spleen tissues, indicating that
the reporter plasmid was stably maintained in the bacteria
during the infection.
Imaging of lung tissue ex vivo
To test whether imaging of infected lungs ex vivo could also
provide a rapid way to assess bacterial burden, all lungs har-
vested during the experiment described in Figure 3 were
imaged using the IVIS system before processing for cfu
(Figure 4). Fluorescence was quantified by ROI analysis (Living
Image software) and increased steadily over time in accordance
with cfu data (Figure 4b). A first signal could be detected in one
lung infected with Mtb Charge3 on day 7. Stronger specific
signals were detected in all lungs on days 13 and 15 after infec-
tion with Mtb Charge3, whilst lungs infected with Mtb H37Rv WT
did not show any specific fluorescent signal (Figure 4a). The mea-
sured fluorescence correlated well with the bacterial load in each
organ (r¼0.7564, P¼0.0011; Figure 4c). A linear regression ana-
lysis was performed to calculate the detection limit of this assay
(Figure 4c). Based on the notion that any detectable amount of
reporter bacteria should emanate higher amounts of fluores-
cence than WT bacteria, Y was set based on the average
amount of fluorescence detected in the five Mtb H37Rv
WT-infected lungs. The average fluorescence measured was
3.2×1025, and the threshold for the background signal (Y) was
arbitrarily set to 3.5×1025. From this, the detection limit for
the excised organ was calculated as 1.1×107 cfu/lung.
To further improve the sensitivity, as well as resolution of the
fluorescent signal, we employed a custom-built LS system,
where the laser scans across the whole organ and captures
the emitted light in a single image. To test whether this system
improved upon the IVIS imaging, excised lungs from CB-17
SCID mice infected with Mtb Charge3, or Mtb H37Rv WT-infected
lungs as negative controls, were imaged (Figure 5). Mice were
killed on day 12, 15 or 18 after infection, their lungs aseptically
removed and images of all lungs acquired on both systems. To
demonstrate the range of signals measured, three lungs with
109
108
*
**
107
Exp. 1 (Day 5)
Lung(a)
(b)
(c)
Exp. 2 (Day 5)
106
105
cf
u/
or
ga
n
104
103
102
101
100
H3
7R
v
Ch
arg
e3
Ch
err
y3
Ch
err
y1
0
H3
7R
v
As
ta3
109
108
107
Exp. 1 (Day 20)
Lung
Exp. 2 (Day 16)
106
105
cf
u/
or
ga
n
104
103
102
101
100
109
108
107
106
105
104
103
102
101
100
H3
7R
v
Ch
arg
e3
Ch
err
y3
Ch
err
y1
0
H3
7R
v
As
ta3
Exp. 1 (Day 20)
Spleen
Exp. 2 (Day 16)
cf
u/
or
ga
n
H3
7R
v
Ch
arg
e3
Ch
err
y3
Ch
err
y1
0
H3
7R
v
As
ta3
Figure 1. Fitness testing of fluorescent reporter strains of Mtb. In two
separate experiments (Exp. 1 and Exp. 2) CB-17 SCID mice (n¼5) were
infected with fluorescent or WT strains of Mtb via the intranasal route.
(a) cfu in lung tissue at the early timepoint (5 days after infection). (b)
cfu in lung tissue at later timepoints (16 and 20 days after infection). (c)
cfu in spleen tissue at later timepoints (16 and 20 days after infection).
Each data point represents an individual organ, and horizontal lines
represent the means. Input inocula/mouse: Exp. 1: H37Rv, 2.9×103 cfu;
Charge3, 1.2×103 cfu; Cherry3, 2×103 cfu; Cherry10, 2.3×103 cfu;
Exp. 2: H37Rv, 1×104 cfu; Asta3, 4×103 cfu. **P,0.01; *P,0.05.
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low and three with high fluorescent signals are shown, with IVIS
images shown in the top row and corresponding LS images of
the same lung shown underneath (Figure 5a). The images
taken with the LS system showed clearly superior resolution of
the fluorescent signal when compared with the IVIS images.
However, a difference in fluorescence intensity was not observed
between the two systems, suggesting comparable sensitivity of
both approaches with our current set-up.
Ex vivo imaging for drug efficacy testing
Since ex vivo imaging of infected lungs using the IVIS system
proved to be a viable method to assess bacterial burden as an
alternative to cfu assays, we tested whether this was also true
for the LS system, and whether both approaches could be used
to document the effect of antibiotic treatment, providing a
faster, more efficient way to test new anti-TB drugs. SHO mice
were infected intranasally with Mtb Charge3 and given daily
doses of moxifloxacin (50 mg/kg body weight) or saline by oral
gavage on days 1–7 after infection. One group of mice was
infected with Mtb H37Rv WT as negative control for imaging
and was given saline by oral gavage together with the rest of
the mice. For each timepoint (on day 1 before treatment was
started and on days 9, 19 and 28 after infection), lungs were
aseptically removed and imaged in both IVIS and LS systems
before processing for cfu (Figures 6 and 7).
A specific signal was detected as early as day 9 in lungs from
saline-treated infected mice, and ROI analysis showed a
1.37-fold increase in fluorescence over the signals measured in
lungs from moxifloxacin-treated mice using the IVIS system
and a 2.07-fold increase using the LS system (P¼0.0079 for
both; Figure 6). Fluorescence increased steadily over time in the
saline-treated group up to day 28. In the moxifloxacin-treated
group, fluorescence was lower than in the saline group on day
19 (2.89-fold for IVIS and 3.99-fold for LS) and day 28
(1.41-fold for IVIS and 2.33-fold for LS), but the difference was
only significant on day 19 (P¼0.0159 for both; Figure 6b and
c). Bacterial burden in the lungs as assessed by cfu assay
increased over time in the saline-treated group, but dropped
slightly up to day 19 in the moxifloxacin-treated group
(2.3-fold decrease from day 1 to day 19; Figure 7a) with a signifi-
cant difference between the two groups on days 9 and 19
(P¼0.0079 and P¼0.0159, respectively), but not on day 28
(P¼0.4206). Data from the saline group of this experiment
were used to correlate cfu to the fluorescent signals measured
by either of the two imaging systems (Figure 7b and c). Better
correlation was achieved when using the LS system compared
with the IVIS system, although in both cases the correlation
was highly significant (r¼0.9223, P,0.0001 and r¼0.7992,
P,0.0001, respectively). Linear regression analysis was used to
calculate the detection limit of this assay (Figure 7b and c). Y
was set based on the average amount of fluorescence detected
in Mtb H37Rv WT-infected lungs on day 28. The measured
average fluorescence (n¼5) was 8.99×1026 for the IVIS
system and 351.9 for the LS system, and the threshold for the
background signal (Y) was arbitrarily set to 1×1025 and 400,
respectively. Using these values, the detection limit was
calculated as 5.90×104 cfu/lung for the IVIS system and
7.51×104 cfu/lung for the LS system, providing 1000-fold
improvement over the in vivomethod and corroborating compar-
able sensitivity of the two imaging systems.
Discussion
Here we provide the first known report of detection of Mtb in live
animals by fluorescence non-invasive imaging during progressive
infection. We investigated the suitability for in vivo imaging of
four different red fluorescent Mtb reporter strains, and
found that all strains retained virulence when compared with
the parental H37Rv WT strain despite the expression of
plasmid-encoded FPs. While mean bacterial burdens were com-
parable between all strains at day 20 post-infection, we observed
a strong fluorescent signal only from mice infected with the
Charge3 strain. Better detectability over other reporter strains is
H37Rv
(Day 20)
(a) (b)
(c) (d)
H37Rv
(Day 20)Charge3 (Day 20) Cherry10 (Day 20)
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H37Rv
(Day 16)Cherry3 (Day 20) Asta3 (Day 16)
Figure 2. In vivo imaging of Mtb reporter strains. CB-17 SCID mice infected in Figure 1 with Mtb Charge3, Cherry3, Cherry10, Asta3 or the parental Mtb
H37Rv WT strain were imaged using the IVIS system at 16 days (d) or 20 days (a–c) post-infection. Images were taken using the following settings:
(a–c) excitation filter 605 nm, emission filter 660 nm, f-stop 2, exposure time 3 s; (d) excitation filter 570 nm, emission filter 620 nm, f-stop 2,
exposure time 5 s. Non-specific fluorescence was recorded using a lower excitation wavelength [(a–c) 500 nm; (d) 465 nm]. Fluorescence intensity
is presented as efficiency and depicted as false colour, where dark red corresponds to the lowest intensity and yellow to the highest intensity.
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most likely due to the following two factors. Firstly, absorption of
light by tissue depends on the wavelength and declines rapidly
between 580 and 650 nm.21 Therefore, a difference of
25 nm in the maximum emission wavelength (i.e. a shift from
610 to 635 nm between mCherry and Turbo-635, respectively)
will have a considerable impact on signal detection in vivo. Sec-
ondly, Mtb Charge3 was previously found to be brighter than Mtb
Cherry3 and Mtb Asta3 in liquid cultures in vitro.20 Based on the
high level of fluorescence observed after in vivo imaging, Charge3
was chosen for further studies. We were able to visualize
8×107 bacteria of Mtb Charge3 in the lungs of living animals
from day 12 to day 15 after infection. This is based on detection
of the first specific signal on day 12 after infection. Specificity
was defined as the significant increase in fluorescence in Mtb
Charge3-infected mice over Mtb H37Rv WT-infected controls.
We observed some variation of background fluorescence over
time in whole Mtb H37Rv WT-infected animals. Therefore, we
recommend the inclusion of a control group of mice infected
with non-fluorescent bacteria at each timepoint of imaging.
Importantly, Mtb Charge3 maintained stable expression of the
reporter FP during the entire course of infection, as indicated
by the colour of colonies grown in cfu assays. This method
could therefore be useful for high-dose models of acute Mtb in-
fection employed in drug testing or therapeutic vaccine studies.
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Figure 3. Time course of infection of CB-17 SCID mice with Mtb Charge3. Groups of CB-17 SCID mice (n¼5/group) were infected via the intranasal
route with Mtb Charge3 or the parental Mtb H37Rv WT strain. (a) The same representative group of five animals (indicated by M1–M5) is shown in
each image. Images were acquired at the indicated timepoints with an exposure time of 10 s. Fluorescence intensity is presented as efficiency
and depicted as false colour, where dark red corresponds to the lowest intensity and yellow to the highest intensity. (b) and (c) Bacterial burden
of Mtb Charge3 as cfu in lung and spleen, respectively, over the course of the infection. Each data point represents an individual organ, and
horizontal lines represent the means. (d) Quantification of fluorescence intensity over the thoracic area only as determined by ROI analysis. All
animals were included in this analysis up to the timepoint when they were killed for cfu analysis or because they had reached their humane
endpoint (Charge3 infected: n¼25 for days 4 and 7; n¼20 for day 12; n¼15 for day 15; H37Rv infected: n¼5 for all timepoints). Data are
presented as means+SEM (Charge3, filled circles; H37Rv, open squares). Due to logistical constraints within the containment suite, images were
acquired on day 12 after infection, whilst bacterial burden was determined the following day (day 13). Input inocula/mouse: Charge3,
1.7×104 cfu; H37Rv, 2×103 cfu. **P,0.01. ND, not determined.
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A previous report has described imaging in the lungs of living
mice of an M. bovis BCG vaccine strain expressing tdTomato, but
animals were imaged immediately after infection, not allowing
time for the infection to evolve naturally.28 More recently, the
same group developed a new method where fluorescence
emitted from a reporter enzyme reaction is measured. Using
this method, they were able to detect as few as 104 cfu BCG
and 106 cfu Mtb in the lungs of living mice when substrate was
given immediately after infection.29 The authors also report a
significant difference in fluorescent signal after 6 days of treat-
ment with isoniazid and rifampicin in mice infected with
106 cfu Mtb. However, this technique requires the administration
of exogenous fluorogenic substrate 24–48 h before imaging,
whilst in our system imaging can be performed at any time,
independently of exogenous substrate administration.
Where the detection of lower numbers of bacteria is desirable,
an ex vivo approach represents a useful alternative to in vivo
imaging. This is still an endpoint method where the animal has
to be killed, but allows instant assessment of bacterial load
and location and of the effect of a new drug or vaccine
without the additional 4–6 weeks needed for cfu assays. In
this way, informed decisions regarding the infection status of
the remaining animals can be made immediately during the
course of an experiment, e.g. whether treatment should be
initiated or delayed until a certain bacterial burden is reached.
Using two different imaging systems we have shown that the
bacterial burden correlates to the fluorescent signals measured
in excised lungs. A high-dose infection led to a high bacterial
burden in the lungs of CB-17 SCID mice, accompanied by macro-
scopically visible changes in lung morphology with a highly con-
gested and inflamed appearance on days 12 and 15 after
infection (data not shown). The onset of weight loss in animals
(data not shown) was observed within 2 weeks after infection,
and a detection limit for ex vivo lung imaging of 1.1×107 cfu
was found. In an attempt to increase sensitivity in vivo by elim-
inating the need to remove the animal’s fur, we infected SHO
mice but found that the growth kinetics of Mtb Charge3 were
slower in this mouse strain when compared with those observed
in CB-17 SCID mice, and specific fluorescent signals were not
detected in these mice by in vivo imaging up to day 28 after in-
fection (data not shown). The saline-treated SHO mice at this
timepoint were in an earlier stage of infection compared with
the CB-17 SCID mice at days 12–15, and did not show weight
loss, any symptoms of disease or gross changes in the visible ap-
pearance of lung tissue at the time when ex vivo imaging of
lungs was performed. Again, bacterial burden and fluorescent
signals obtained from SHO mice correlated, but here a much
lower limit of detection was evident, as an average bacterial
Table 2. Stability of marker protein expression in Mtb Charge3
Time (days)
Lungs Spleen
% coloured (mean) SD % coloured (mean) SD
1 91.4 5.47 ND ND
7 94.8 2.91 ND ND
13 93.1 3.11 91.0 6.67
15 93.3 2.96 94.2 5.95
ND, not determined.
The mean percentage of red-coloured colonies recovered from lung or
spleen tissue from CB-17 SCID mice at indicated timepoints after
infection is shown. The mean and SD were calculated from organs of
five individual mice per timepoint. 15.0
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Figure 4. Ex vivo fluorescence imaging of lungs harvested from Mtb
Charge3-infected mice. (a) Groups of CB-17 SCID mice (n¼5) were
infected intranasally with Mtb Charge3 or H37Rv WT, then animals
were killed and lungs aseptically removed at 7, 13 or 15 days after
infection as indicated. (b) Fluorescence (red line) was quantified by
drawing an ROI over the thoracic area using Living Image software.
Fluorescence is shown as efficiency. cfu data (black broken line) are the
same data shown in Figure 3, but are included here for comparison.
Data are presented as means+SEM of five individual mice.
(c) Correlation of cfu and fluorescence intensity of lungs shown in (a).
Each data point represents an individual organ. The number of cfu X
for a given fluorescence measurement Y is described by the equation
shown, which was obtained from linear regression analysis. Input
inocula/mouse: Charge3, 1.7×104 cfu; H37Rv, 2×103 cfu. r is the
Pearson correlation coefficient. **P,0.01.
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burden of 2×105 cfu/lung on day 19 could be readily detected in
both imaging systems, and the calculated detection limits are
5.90×104 cfu/lung for the IVIS system and 7.51×104 cfu/lung
for the LS system. Taking into consideration both the images
obtained and the calculated detection limits, and allowing a
margin for error, we estimate that both imaging systems are in
practice capable of detecting 1–2×105 cfu/lung, which,
however, is reduced in CB-17 SCID mice. The reason for this dif-
ference is as yet unclear. One could speculate that, due to the
advanced stage of the infection in CB-17 SCID mice, the
amount of FP produced by Mtb was declining, or that lung in-
flammation changed the physical properties of the tissue,
thereby reducing tissue penetration and the detectable
amount of light emitted from bacteria in this organ. Although
the plasmid from which the FP is expressed is retained through-
out the course of the infection, it is not possible to determine the
amount of fluorescence emanating from individual bacteria at
the time of imaging using a cfu assay. In our opinion, the SHO
mouse is better suited for the TB experiments proposed here
due to the slower infection dynamics and no macroscopically
visible changes in lung morphology at days 9 and 19 after
infection.
All experiments in this study were performed using immuno-
deficient animals. Whilst detection of Mtb fluorescent reporter
strains in immune-competent mice using in vivo imaging will
be challenging due to lower bacterial loads, we expect that our
ex vivo imaging approach in combination with a high-dose infec-
tion and early treatment may also be employed for drug efficacy
testing under immune pressure. The assay proposed here is
aimed at fast, preliminary assessment of new anti-tuberculosis
compounds. Gross pathological changes of lung tissue which
are only occurring later in infection are unlikely to influence de-
tection limits significantly. The detection limits we report here
are determined by variables of the experimental set-up, such
as the sensitivity of currently available CCD cameras and bright-
ness and wavelength of FPs. In future, the development of more
sensitive hardware and detection methods and new, bright near-
infrared FPs will surely improve on the current detection
limits.30,31
When comparing the IVIS and LS systems, no difference in
sensitivity was found. However, spatial resolution of the fluores-
cent signal was superior in the LS system compared with the IVIS
system. This could facilitate more detailed localization of myco-
bacteria within the lung tissue, e.g. to determine where bacteria
remain in the lung after antibiotic treatment or from where
samples should be taken for follow-up studies by microscopy.
Other differences between the two systems include ease of
use, image collection time per animal and flexibility of the hard-
ware set-up. With its commercial nature, the IVIS system is very
user friendly and the software is intuitive, offering simple and
time-efficient experimental set-up and operation; however, the
hardware set-up has limited flexibility. In contrast, the LS
system is custom-built, making it slightly more difficult to use,
but its flexible set-up, including laser lines and emission filters,
can be freely adjusted and optimized according to the user’s
requirements. In essence, the IVIS system is ideal for quick
acquisition of low-resolution images, whilst the LS system is
capable of producing more detailed images but with greater
time expenditure.
To develop an efficient assay to test new antibiotics in vivo, we
adopted an infection model recently developed by Rullas et al.,32
in which antibiotic treatment of mice is initiated 1 day after
infection and the effect assessed 8 days later. In that study,
moxifloxacin in particular gave very reproducible results and
was therefore used here to validate our imaging approach.
Indeed, after administering only seven daily doses of the drug,
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Figure 5. Ex vivo imaging of lungs from mice infected with Mtb Charge3 or H37Rv, comparing IVIS and LS systems. (a) CB-17 SCID mice were infected
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we found a significant difference in fluorescence between lungs
from saline- and moxifloxacin-treated mice on days 9 and 19
after infection using both the IVIS and the LS system. The differ-
ence between the treated and control groups at day 19 was
more pronounced than at day 9, and was greater using the LS
system compared with the IVIS system (3.99-fold and
2.89-fold, respectively). Notably, the measurements obtained
with the IVIS system showed less variation between individual
mice within each group. The bacterial load in lungs paralleled
the fluorescent signal intensities, with the exception of the
moxifloxacin-treated group on day 19 after infection, when the
number of bacteria was decreased, whilst the fluorescence was
increased compared with day 9. This phenomenon could be
explained by the presence of two sub-populations of bacteria,
one that still carries the FP and is viable but non-culturable,
and another that multiplies while expressing the FP. This could
result in the net number of bacteria detected in the cfu assay
staying at approximately the same level whilst overall fluores-
cence increases. As a consequence, the correlation between
cfu and fluorescence in the moxifloxacin-treated mice was less
stringent and only data from saline-treated mice were included
to calculate the detection limits. It has recently been shown
for Salmonella that a substantial fraction of intracellular bacteria
are viable but do not proliferate, a scenario also imaginable for
Mtb, as it is well known that Mtb bacilli can enter a dormant-like
state inside the host.11,33 With the methods used in this study it
is not possible to determine the metabolic state of the bacilli in
vivo or the influence of the metabolic state on fluorescence in-
tensity. We can, however, exclude fluorescence signals from re-
sidual FPs after mycobacterial cell death since treatment with
bactericidal antibiotics in vitro led to rapid loss of fluorescence.20
Importantly, the significant difference between bacterial
numbers determined by cfu assay in moxifloxacin-treated and
control mice on days 9 and 19, but not on day 28, mirrors the
differences in fluorescence intensities measured and under-
scores the validity of our imaging assay.
In vivo testing of anti-TB drugs is time-consuming and expen-
sive because most current models are designed to mimic
therapy in humans as closely as possible, keeping the initial in-
fectious dose low and initiating treatment 2–4 weeks after infec-
tion, when a high bacterial burden in the lung is reached.34–37
Subsequent treatment is given for several weeks or months,
and experiments usually include a relapse group to test
whether a drug has sterilizing capability, which further extends
the duration of the whole experiment up to 4 months or more.
Our assay aims at fast, preliminary in vivo assessment of new
anti-TB drugs by screening for activity of compounds against rep-
licating bacteria, which could guide subsequent longer term in
vivo studies, including combinatorial therapy. Other fast assays
designed for similar purposes include the use of interferon
g-knockout mice, in which Mtb grows rapidly when left untreated,
and therefore activity of a new drug can be assessed after only
eight treatment doses by the difference in bacterial burden in
the treated and untreated groups.38 However, treatment is
only started 18 days after infection following a low-dose Mtb in-
fection, and requires a further 4 weeks for completion of the cfu
assay. Therefore, the whole assay takes 8 weeks to complete.
Our assay indicates after 19 days whether a new drug has
anti-TB activity or not. Furthermore, the location of the mycobac-
teria can be determined, while lengthy cfu assays can be cut out
of the testing process. More recently, the use of intravenous
infection with Mycobacterium smegmatis as a fast-growing
model organism for anti-TB drug testing has been suggested,39
although in this model bacterial load was highest in the
spleens, and not lungs, of mice. It therefore does not represent
a typical Mtb infection, which manifests mainly in the lungs.
To extend the fluorescent Mtb reporter system to isolates of
more relevance for drug testing, Carroll and Parish have also
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Figure 7. Bacterial burden of lungs from SHO mice infected with Mtb
Charge3 and treated with moxifloxacin or saline. (a) Lungs of mice
from Figure 6 were assayed for bacterial burden at different timepoints
after treatment with saline (filled circles) or moxifloxacin (open circles)
as indicated. Each data point represents an individual organ and
horizontal lines represent the means. (b) and (c) Correlation of cfu in
lungs of saline-treated mice to fluorescence measurements of lungs ex
vivo using the IVIS or LS system. Each data point represents an
individual organ. The number of cfu X for a given fluorescence
measurement Y is described by the equations shown, which were
obtained from linear regression analysis. r is the Pearson correlation
coefficient. ***P,0.001; **P,0.01; *P,0.05; ns (not significant) P.0.05.
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produced fluorescent derivatives of the clinical isolate Mtb
CDC1551 (P. Carroll and T. Parish, unpublished data). Differences
in the stability and protein expression of this strain were not
observed when compared with Mtb H37Rv, suggesting that our
system is transferable to clinical and even drug-resistant isolates
of Mtb.
In summary, we have presented evidence that fluorescent
reporter strains of Mtb can be visualized by non-invasive optical
imaging in living animals at the late stage of an acute, progres-
sive infection in immunodeficient mice. We have also shown that
ex vivo imaging of target organs such as the lung is a useful and
time-efficient method with which to assess bacterial burden
and location within the organ with increased sensitivity com-
pared with in vivo imaging of whole animals. This ex vivo
method allowed us to visualize and quantify the effect of anti-
biotic treatment using either an IVIS system or a custom-built
LS system. These imaging assays based on fluorescent Mtb
reporter strains can now provide novel tools for the analysis
of new drugs, in order to speed up the process of identifying
promising candidates for the treatment of TB.
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